(6-hydroxybenzofuran-3-yl)acetic acid ethyl ester | 1380792-77-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (6-hydroxybenzofuran-3-yl)acetic acid ethyl ester
• 英文别名: Ethyl 2-(6-hydroxybenzofuran-3-yl)acetate；ethyl 2-(6-hydroxy-1-benzofuran-3-yl)acetate
• CAS: 1380792-77-7
• 化学式: C₁₂H₁₂O₄
• 分子量: 220.225
• InChiKey: STUUQELNMSZBHY-UHFFFAOYSA-N

物化性质

• 沸点：
  233.3±9.0 °C(Predicted)
• 密度：
  1.265±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (6-hydroxybenzofuran-3-yl)acetic acid ethyl ester 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 24.25h， 生成
  参考文献：
  名称：

  EP3848371

  摘要：

  公开号：
• 作为产物：
  描述：

  Ethyl 2-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-yl)acetate 在 双氧水 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 (6-hydroxybenzofuran-3-yl)acetic acid ethyl ester
  参考文献：
  名称：

  [EN] HETEROARYL-3-PIPERIDINEDIONE COMPOUND AND USE THEREOF
  [FR] COMPOSÉ HÉTÉROARYLE-3-PIPÉRIDINEDIONE ET SON UTILISATION
  [ZH] 杂芳-3-哌啶二酮类化合物及其应用

  摘要：

  一种杂芳-3-哌啶二酮类化合物及其应用，具体公开了式(II)所示化合物及其药学上可接受的盐。

  公开号：

  WO2023001028A1

文献信息

• [EN] INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS DE LA PRODUCTION DE LEUCOTRIÈNE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015009611A1

  公开（公告）日：2015-01-22

  The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the aryl pyrazoles of the present invention, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及芳基吡唑及其药用可接受盐。本发明的芳基吡唑可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含本发明的芳基吡唑的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• Synthesis and Preliminary Evaluation of Benzofuran-Oxadiazole Conjugates as Potential Antitubercular Agents
  作者：Veerabhadrayya S. Negalurmath、Obelannavar Kotresh、Mahantesha Basanagouda

  DOI：10.14233/ajchem.2019.21831

  日期：2019.3

  the compounds were screened for preliminary antitubercular activity against Mycobacterium phlei and Mycobacterium tuberculosis H37RV. Among all the target compounds, the compound possessing chlorine (7k, MIC 1.56 μg/mL) and bromine (7m, MIC 1.56 μg/mL) on 6th position of benzofuran showed highest activity against Mycobacterium phlei. Whereas, bromine on either 5th position (7l, MIC 3.125 μg/mL) or 6th

  在本研究中，设计、合成了一系列苯并呋喃-恶二唑缀合物7(ao)，并通过IR、1H NMR、13C NMR和质谱数据进行表征。所有化合物均针对草分枝杆菌和结核分枝杆菌 H37RV 的初步抗结核活性进行了筛选。在所有目标化合物中，苯并呋喃6位上具有氯（7k，MIC 1.56 μg/mL）和溴（7m，MIC 1.56 μg/mL）的化合物对草分枝杆菌表现出最高的活性。而苯并呋喃上第 5 位（7l，MIC 3.125 μg/mL）或第 6 位（7m MIC 3.125 μg/mL）上的溴对结核分枝杆菌 (H37 RV) 表现出最高活性。
• INHIBITORS OF LEUKOTRIENE PRODUCTION
  申请人：ABEYWARDANE Asitha

  公开号：US20140031339A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A 1 , A 2 , L 1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A 4 hydrolase (LTA 4 H) and treating LTA 4 H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中A1、A2、L1和B的定义如本文所述。式(I)的化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗LTA4H相关疾病。本发明还涉及包括式(I)的化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的过程。
• From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3β Inhibitors That Suppress Proliferation and Survival of Pancreatic Cancer Cells
  作者：Irina N. Gaisina、Franck Gallier、Andrei V. Ougolkov、Ki H. Kim、Toru Kurome、Songpo Guo、Denise Holzle、Doris N. Luchini、Sylvie Y. Blond、Daniel D. Billadeau、Alan P. Kozikowski

  DOI：10.1021/jm801317h

  日期：2009.4.9

  Recent studies have demonstrated that glycogen synthase kinase 3 beta (GSK-3 beta) is overexpressed in human colon and pancreatic carcinomas, contributing to cancer cell proliferation and survival. Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl)maleimides, potent GSK-3 beta inhibitors. Some of these compounds show picomolar inhibitory activity toward GSK-3 beta and an enhanced selectivity against cycl in-dependent kinase 2 (CDK-2). Selected GSK-3 beta inhibitors were tested in the pancreatic cancer cell lines MiaPaCa-2, BXPC-3, and HupT3. We determined that some of these compounds, namely compounds 5, 6, 11, 20, and 26, demonstrate antiproliferative activity against some or all of the pancreatic cancer cells at low micromolar to nanomolar concentrations. We found that the treatment of pancreatic cancer cells with GSK-3 beta inhibitors 5 and 26 resulted in suppression of GSK-3 beta activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis. The present data suggest a possible role for GSK-3 beta inhibitors in cancer therapy, in addition to their more prominent applications in CNS disorders.
• PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2885285B1

  公开（公告）日：2016-10-19